To fund its initiatives to deliver MDMA therapy to market place, MAPS Public Reward Company (PBC) — MAPS’ pharma subsidiary, which bifurcated in 2014 but did not accept financial commitment in return for equity and could not safe the $70 million necessary to shift ahead — has morphed into the for-financial gain Lykos Therapeutics.This protoco